Cost savings of reducing opioid prescribing for the treatment of people with low back pain in general practice: a modelling study.

Background: Low back pain (LBP) is the leading cause of disability worldwide. Contrary to clinical guidelines, opioids are frequently prescribed early in the management of LBP in primary care, leading to potential harm and downstream healthcare costs. The objective of this study was to model the one-year impacts of strategies that reduce opioid prescribing for low back pain (LBP) in primary care on healthcare costs and overdose deaths Australia-wide and explore the potential for such strategies to be cost-neutral.

One-step antifouling coating of polystyrene using engineered polypeptides.

Unwanted nonspecific adsorption caused by biomolecules influences the lifetime of biomedical devices and the sensing performance of biosensors. Previously, we have designed B-M-E triblock proteins that rapidly assemble on inorganic surfaces (gold and silica) and render those surfaces antifouling. The B-M-E triblock proteins have a surface-binding domain B, a multimerization domain M and an antifouling domain E.

Reinvestigation into the role of lipopolysaccharide Glycosyltransferases in protein glycosylation.

Protein glycosylation has been considered as a fundamental phenomenon shared by all domains of life. In , glycosylation of flagellins A and B with pseudaminic acid have been rigorously confirmed and shown to be essential for flagella assembly and bacterial colonization. In addition to flagellins, several other proteins including RecA, AlpA/B, and BabA/B in have also been reported to be glycosylated and to be dependent on the lipopolysaccharide (LPS) biosynthetic pathway.

Pandemic driven preoperative moderate hypofractionated radiotherapy for soft tissue sarcomas.

Purpose: Moderate hypofractionation was adopted to reduce hospital visits during the COVID-19 pandemic aiming to maintain treatment efficacy for soft tissue sarcoma (STS) patients, shifting preoperative schedules from 25 fractions of 2 Gy to 14-15 fractions of 3 Gy. This study evaluates the clinical implications and outcomes of this schedule, focusing on wound complications, radiation toxicity, local tumour control, and distant metastases.

Patients And Methods: Data was collected from patients treated between 01 and 01-2020 and 31-12-2023.

Long-term survival of participants in the PASART-1 and PASART-2 trials of neo-adjuvant pazopanib and radiotherapy in soft tissue sarcoma.

Objective: This study aims to assess the long-term safety and efficacy of adding pazopanib to neo-adjuvant radiotherapy followed by surgery in patients with high-risk non-metastatic soft tissue sarcoma of the trunk and extremities treated in the PASART-1 and PASART-2 trials, as well as to compare the PASART cohorts to a control cohort receiving standard treatment during the same time period from the Netherlands Cancer Registry (IKNL) to investigate if adding pazopanib improves Overall Survival (OS).

Methods: Updated follow-up data on disease control, survival and long-term toxicities of the PASART-trials were extracted from electronic patient records. The effect of adding pazopanib to neo-adjuvant radiotherapy on OS was investigated by comparing the combined PASART cohorts to the IKNL cohort via direct comparison and exact matching analysis.